The need for new antimalarial drugs is dire, and this work identifies attractive lead compounds for drug development as well as important probes for dissecting a key antimalarial drug target, the non-mevalonate pathway for isoprenoid biosynthesis. This pathway does not exist in humans, making it an extremely attractive, specific target for antimalarial drug design.
- Dr. Umesh Desai, VCU, is Awarded a 5 year Grant
- Center for Molecular Imaging – VCU Supports Research Virginia-wide
- Virginia Tech Center for Drug Discovery Researcher receives $1.2 million to find Compounds to Treat Fatty Liver Disease
- Frank Gupton receives a $25M award from the Gates foundation
- VirginiaCancerRx in the News!